Abstracts tagged "rheumatoid arthritis (RA) and cardiovascular disease"

Abstract Number: 896 • 2019 ACR/ARP Annual Meeting
Hydroxychloroquine Use and Cardiovascular Events Among Patients with Systemic Lupus Erythematosus and Rheumatoid Arthritis
April Jorge¹, Na Lu ², Hyon K. Choi ¹, John Esdaile ³, Diane Lacaille ⁴ and J. Antonio Avina-Zubieta ⁵, ¹Massachusetts General Hospital, Boston, MA, ²Massachusetts General Hosptial, Boston, MA, ³Arthritis Research Canada and the University of British Columbia, Richmond, BC, Canada, ⁴Arthritis Research Canada and University of British Columbia, Vancouver, BC, Canada, ⁵Arthritis Research Canada and the University of British Columbia, Vancouver, BC, Canada
Background/Purpose: Hydroxychloroquine (HCQ) is near-universally recommended for patients with SLE and is often used in the treatment of RA. Use of HCQ has been associated…
Abstract Number: 922 • 2019 ACR/ARP Annual Meeting
Improved Incidence of Cardiovascular Disease in Patients with Incident Rheumatoid Arthritis in 2000s: A Population-Based Cohort Study
Elena Myasoedova¹, John Davis ¹, Veronique Roger ¹, Sara Achenbach ¹ and Cynthia Crowson ², ¹Mayo Clinic, Rochester, MN, ²Mayo Clinic Rochester, Rochester
Background/Purpose: Increased burden of cardiovascular disease (CVD) in patients with rheumatoid arthritis (RA) as compared to the general population is well recognized. Several studies suggested…
Abstract Number: 2337 • 2019 ACR/ARP Annual Meeting
Treat to Target Is Not Linked to Best Myocardial Strain Indices: Is There Really a Myocardial Dysfunction Directly Associated with Disease Activity?
Alisson Pugliesi¹, Hugo Nourani ¹, José Roberto Matos Souza ¹ and Manoel Bertolo ², ¹University of Campinas, Campinas, Sao Paulo, Brazil, ²University of Campinas, Campinas, Brazil
Background/Purpose: The risk of developing heart failure (HF) is twice as high in the RA population. It is hypothesized that, in addition to the atherosclerotic…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].